BioSpace News Archive

Brii Biosciences Limited announced that its strategic partners, Vir Biotechnology, Inc. and VBI Vaccines, Inc., presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral infection at the European Association for the Study of the Liver Congress 2023 that further support the clinical evaluation of Brii Bio’s assets as a potential best-in-class functional cure for chronic HBV infection.

MoonLake Immunotherapeutics announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa.

The American Diabetes Association® published updates in the Standards of Care in Diabetes—2023 based on the latest scientific research and clinical trials.

Pivotal data from the Phase 3 XTEND-Kids study evaluating ALTUVIIIOTM [Antihemophilic Factor, Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis, a first-in-class, high-sustained factor VIII replacement therapy, in previously treated patients younger than 12 years of age with severe hemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis in Montreal, Canada.

Pivotal data from the Phase 3 XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor, Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis in previously treated patients younger than 12 years of age with severe haemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis in Montreal, Canada.

SPR Therapeutics has been selected as a Top Workplaces honoree for the second year in a row by cleveland.com and The Plain Dealer.

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced that it entered into definitive agreements with Qpex Biopharma and third parties in connection with the acquisition of Qpex by Shionogi.

Ascletis Pharma Inc. announces the poster presentation of ASC42, a novel farnesoid X receptor agonist, in combination with PEGylated interferon and entecavir in chronic hepatitis B patients with 12-week treatment at European Association for the Study of the Liver CONGRESS 2023.

Takeda presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura, and pharmacokinetics characteristics of TAK-755, as well as long-term data on TAK-755 prophylaxis from a Phase 3b continuation study.

The American Diabetes Association® published updates to the Standards of Care in Diabetes—2023 on the use of teplizumab in delaying the onset of type 1 diabetes.